Fund of the week: Neil Woodford’s stunning solo career

Since leaving Invesco Perpetual last year, Neil Woodford has continued to beat the market with his new fund.

746-woodford-b

Since last June, the fund has delivered a 19.6% return. Over the same period the FTSE All Share returned just 7.8%, while the UK equity income sector returned 10.7%. In fact, says Richard Evans in The Sunday Telegraph, Woodford generated the best returns in his peer group of 85 funds.

Meanwhile, his old fund, the Invesco Perpetual High Income Fund, managed 12.9% still creditable, but well behind Woodford.The fund's remit is to deliver income and capital growth by investing in UK companies. The annual management fee is 1% fordirect investors with minimum investment of £150,000, otherwise it is 0.75%. Investors have "flocked" to it, says Evans it boasts £6.2bn of savers' cash. Most holdings are blue chips, with a focus on tobacco (which might be a problem in the future), defence and pharmaceuticals.

The strong performance was down to a mix of exposure to healthcare and consumer goods, and avoidance of oil and gas, says Shane Hickey in The Guardian. Laith Khalaf of Hargreaves Lansdown adds that Woodford's small caps selection generated 40% of the outperformance, despite accounting for only 15% of the fund.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Other picks include Royal Mail, Babcock and Drax, with 4%-5% of the fund invested in early-stage unquoted firms. Stock picking will continue to be key, as Woodford reckons UK growth will be "modest at best" in the next five years.

Contact: 0870-870 8482

Swipe to scroll horizontally
AstraZeneca7.03%
Imperial Tobacco6.54%
GlaxoSmithKline6.23%
British American Tobacco5.78%
BT4.33%
Allied Minds3.60%
Capita3.57%
Reynolds American3.08%
BAE Systems3.07%
Rolls-Royce2.92%